Higher Rate of Toxicity With No Increased Efficacy When Hydroxyurea Is Added to a Regimen of Stavudine Plus Didanosine and Nevirapine in Primary HIV Infection

Simple item page
dc.contributor.authorZala, Carlos
dc.contributor.authorSalomon, Horacio
dc.contributor.authorOchoa, Claudia
dc.contributor.authorKijak, Gustavo
dc.contributor.authorFederico, Andrea
dc.contributor.authorPerez, Héctor
dc.contributor.authorJulio SG, Montaner
dc.contributor.authorCahn, Pedro
dc.date.accessioned2024-03-05T02:24:28Z
dc.date.available2024-03-05T02:24:28Z
dc.date.issued2002-04-01
dc.descriptionFil: Zala C. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Ochoa C. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Federico A. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Perez H. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Cahn P. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.description.abstractSummary: Twenty-four subjects presenting at a single treatment center with primary HIV infection were enrolled in a pilot study aimed to establish the possible role of hydroxyurea in this setting. Study participants were randomly assigned to receive or not to receive hydroxyurea in addition to stavudine (d4T) plus didanosine (ddI) and nevirapine (NVP). Seventy-five percent of patients without hydroxyurea had plasma HIV RNA below 50 copies/mL at 48 weeks by both intention-to-treat (ITT) and on-treatment (OT) analysis in comparison with 50% (ITT) and 67% (OT) of patients with hydroxyurea (p > .1). A median increase of >200 cells/mm3 was observed from baseline to week 48 whether or not hydroxyurea was included in the regimen. Overall, in 12 patients treated with hydroxyurea, 33 adverse events were reported versus 19 reported for 12 patients who did not receive hydroxyurea (p < .05). Our results suggest that that adding hydroxyurea to a regimen of d4T plus ddI and NVP increases toxicity without improving the antiviral effect.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1097/00126334-200204010-00007
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/209
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesJAIDS Journal of Acquired Immune Deficiency Syndromes;29(4):p 368-373, April 1, 2002
dc.rightsopenAccesses_ES
dc.subjectHydroxyureaes_ES
dc.subjecttoxicityes_ES
dc.subjectHIVes_ES
dc.titleHigher Rate of Toxicity With No Increased Efficacy When Hydroxyurea Is Added to a Regimen of Stavudine Plus Didanosine and Nevirapine in Primary HIV Infectiones_ES
dc.typeArticuloes_ES

Files

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos